Evidence map›Paper›PMID 26879974›Full record

ArticleScientific reports2016

HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation.

Kaifan Dai, Salar N Khan, Yimeng Wang, Linling He, Javier Guenaga, Jidnyasa Ingale, Christopher Sundling, Sijy O'Dell, Krisha McKee, Ganesh Phad and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Kaifan DaiIAVI Neutralizing Antibody Center at TSRI, La Jolla CA.
Salar N KhanIAVI Neutralizing Antibody Center at TSRI, La Jolla CA.
Yimeng WangDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla CA.
Linling HeDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla CA.
Javier GuenagaIAVI Neutralizing Antibody Center at TSRI, La Jolla CA.
Jidnyasa IngaleIAVI Neutralizing Antibody Center at TSRI, La Jolla CA.
Christopher SundlingDepartment of Microbiology, and Tumor Cell Biology Karolinska Institutet, Stockholm SE.
Sijy O'DellVaccine Research Center, Bethesda MD.
Krisha McKeeVaccine Research Center, Bethesda MD.
Ganesh PhadDepartment of Microbiology, and Tumor Cell Biology Karolinska Institutet, Stockholm SE.
Martin CorcoranDepartment of Microbiology, and Tumor Cell Biology Karolinska Institutet, Stockholm SE.
Richard WilsonIAVI Neutralizing Antibody Center at TSRI, La Jolla CA.
John R MascolaVaccine Research Center, Bethesda MD.
Jiang ZhuIAVI Neutralizing Antibody Center at TSRI, La Jolla CA.
Yuxing LiIAVI Neutralizing Antibody Center at TSRI, La Jolla CA.
Gunilla B Karlsson HedestamDepartment of Microbiology, and Tumor Cell Biology Karolinska Institutet, Stockholm SE.
Richard T WyattIAVI Neutralizing Antibody Center at TSRI, La Jolla CA.
Scripps Research Institute · USInternational AIDS Vaccine Initiative · USKarolinska Institutet · SE

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI AHMED, RAFI · 2012 to 2018
$131.5M
Non-Human PrimatesP01AI104722 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WYATT, RICHARD THOMAS · 2014 to 2018
$14.6M
High-resolution definition of B cell responses to HIV Env for immunogen designR01AI102766 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI LI, YUXING · 2013 to 2024
$6.6M
NIAID NIH HHS AI100663NIAID NIH HHS AI104722NIAID NIH HHS P01 AI104722NIAID NIH HHS R01 AI102766NIAID NIH HHS UM1 AI100663
6 · The paper itself

Abstract

The elicitation of HIV-1 broadly neutralizing antibodies following envelope glycoprotein (Env) vaccination is exceedingly difficult. Suboptimal engagement of naïve B cells is suggested to limit these low frequency events, especially at the conserved CD4bs. Here, we analyzed CD4bs-directed monoclonal antibodies (mAbs) elicited by YU2 gp140-foldon trimers in a non-human primate by selective sorting using CD4bs "knock out" trimers. Following two inoculations, the CD4bs-directed mAbs efficiently recognized the eliciting immunogen in their affinity-maturing state but did not recognize CD4bs-defective probes. We reverted these mAbs to their most likely inferred germline (igL) state, leaving the HCDR3 unaltered, to establish correlates of in vitro affinity to in vivo activation. Most igL-reverted mAbs bound the eliciting gp140 immunogen, indicating that CD4bs-directed B cells possessing reasonable affinity existed in the naïve repertoire. We detected relatively high affinities for the majority of the igL mAbs to gp120 and of Fabs to gp140, which, as expected, increased when the antibodies 'matured' following vaccination. Affinity increases were associated with slower off-rates as well as with acquisition of neutralizing capacity. These data reveal in vitro binding properties associated with in vivo activation that result in functional archiving of antigen-specific B cells elicited by a complex glycoprotein antigen following immunization.

Indexed as

AIDS VaccinesAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibody SpecificityB-LymphocytesCD4 AntigensComplementarity Determining Regionsenv Gene Products, Human Immunodeficiency VirusEnzyme-Linked Immunosorbent AssayHIV-1HIV AntibodiesHumansImmunizationKineticsMacaca mulattaAIDS VaccinesAntibodies, MonoclonalAntibodies, NeutralizingCD4 AntigensComplementarity Determining Regionsenv Gene Products, Human Immunodeficiency VirusHIV Antibodies

Identifiers

PMID26879974
PMCPMC4754655
OpenAlexW2412260145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.